Jazz Pharmaceuticals, Inc. and Johnson & Johnson Services, Inc. are Dominating the North America Psychedelic Drugs Market in 2019

North America Psychedelic Drugs Market is expected to grow with the CAGR of 15.8% in the forecast period 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report at https://www.databridgemarketresearch.com/reports/north-america-psychedelic-drugs-market

Psychedelic rugs market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased various strategic developments owing to favourable market scenario.

The major players dealing in psychedelic drugs market are introducing strong range of product portfolio. This has also helped the company to maximize the sales with enhanced product portfolio.

Jazz Pharmaceuticals, Inc. is the dominating player in psychedelic drugs market and the other players in the market includes Johnson & Johnson Services, Inc., Celon Pharma SA, COMPASS, usonainstitute.org, Develco pharma schweiz ag , Doughlas pharmaceuticals limited ,NeuroRX, Inc, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals, LLC., AVADEL PHARMACEUTICALS, PLC among others.

North America Psychedelic Drugs MarketJazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc. headquartered in Dublin, Ireland was incorporated in 2003. The company is engaged in turning biopharmaceutical discoveries into novel changing drugs to treat rare or complex diseases. The company is providing products under the categories medicine (our medicines, drug safety, and medical information), research (pipeline, clinical trials, extended access, and independent scientific research). The company is constantly engaged in the manufacture and development of psychedelic drugs.

  • In October 2020, Jazz Pharmaceuticals, Inc. pediatric narcolepsy patients have received FDA approval for xyram (sodium oxygenate) for excessive daytime sleepiness or cataplexy treatment. The approval will help the company to dominate the market as Xyram is the only and FDA approved treatment for cataplexy in narcolepsy for older patients and excessive daytime sleepiness approved.

It also has direct sales representatives and distributors in North America, Europe through its subsidiaries Jazz Pharmaceuticals Ireland Limited (Ireland), Jazz Financing Eye Designed Activity Company (Ireland), Jazz Capital Limited (Ireland), Jazz Pharmaceuticals, Inc. (U.S.), Celator Pharmaceuticals, Inc. (U.S.) among others

Johnson & Johnson Services, Inc.

Johnson & Johnson Services, Inc. headquartered in New Jersey, U.S. was founded in 1886. The company is engaged in research and development, manufacturing and sales of a wide range of products in the health care sector. The company is providing products under the categories of consumer health products, medical devices and pharmaceutical products. The company operates in the pharmaceutical, medical device and consumer segments. Market focus is under the products pharmaceutical segment. The company is constantly engaged in the manufacture and development of psychedelic drugs.

  • In December 2019, the company has received approval for the marketing of SPRAVATO throughout Europe. This drug is used in combination with SSRI and SNRI for the treatment of resistant depression. The marketing of SPRAVATO as a nasal spray will increase the revenue generation of the company.

The company has widespread presence across the globe such as Europe, Middle East & Africa, Asia-Pacific, and Americas through its subsidiaries Johnson & Johnson Vision Care, Inc. (U.S.), Neutrogena (U.S.), DePuy Synthes (U.S.), Ethicon USA, LLC. (U.S.), and Janssen Global Services LLC (Belgium) among others.